Amgen Analyst Ratings
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $332
Amgen Analyst Ratings
Research Alert: CFRA Adds Amgen Inc. To The High-quality Capital Appreciation Portfolio
Barclays Sticks to Its Hold Rating for Amgen (AMGN)
HSBC Adjusts Price Target on Amgen to $356 From $322
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating
Mizuho Bank: Maintaining the Amgen (AMGN.US) rating, adjusted from neutral to neutral, and adjusted the target price from $223.00 to $235.00.
Amgen Analyst Ratings
Mizuho Maintains Neutral on Amgen, Raises Price Target to $235
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170
Mizuho Securities Raises Amgen's Price Target to $235 From $223
Promising weight loss candidates William Blair and Barclays raise AMGN.US ratings
BMO Capital Maintains Outperform on Amgen, Raises Price Target to $355
Barclays Upgrades Amgen to Equal-Weight, Raises Price Target to $300
Barclays: Amgen (AMGN.US) rating was raised from reduced holdings to a wait-and-see rating, and the target price was adjusted from $230.00 to $300.00.
Amgen Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
RBC Adjusts Price Target on Amgen to $328 From $332, Keeps Outperform Rating